当前位置: X-MOL 学术Diabetes Obes. Metab. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-03-16 , DOI: 10.1111/dom.14032
Kun-Ho Yoon 1 , Jahoon Kang 2 , Se Chang Kwon 2 , Michael E Trautmann 3 , Marcus Hompesch 3 , John Stewart 4 , Christopher H Sorli 5
Affiliation  

To assess the efficacy, safety and pharmacokinetic/pharmacodynamic properties of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist, in patients with type 2 diabetes (T2D).

中文翻译:

依格列那肽在 2 型糖尿病患者中的药代动力学和剂量发现研究。

评估 efpeglenatide(一种长效胰高血糖素样肽-1 受体激动剂)在 2 型糖尿病 (T2D) 患者中的疗效、安全性和药代动力学/药效学特性。
更新日期:2020-03-16
down
wechat
bug